AKT1 and melanoma: Reports are suggesting that overactivation of the PI3K/AKT/mTOR pathway might contribute to the survival of melanoma cells upon BRAF V600E inhibition and that dual targeting of advanced human cancers with inhibitors of the PI3K/AKT/mTOR and RAF/MEK/ERK pathways might be beneficial [7,63].